Form D · Biotechnology
NanoVibronix, Inc.
Elmsford, NY · CIK 0001326706
Offering snapshot reported Sep 13, 2023 · SEC filing
- Reported sold
- $13.5M Offering amount: $13.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 30, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 13, 2023 | Initial | $13,546,513 | No comparison | 1 | SEC filing |
| Jun 29, 2022 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Feb 5, 2021 | Initial | $1,254,206 | No comparison | 3 | SEC filing |
| Dec 11, 2020 | Initial | $6,562,500 | No comparison | 13 | SEC filing |
| Aug 18, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
| Jul 6, 2020 | Initial | $450,000 | No comparison | 1 | SEC filing |
| Apr 3, 2017 | Initial | $250,000 | No comparison | 3 | SEC filing |
| Apr 3, 2017 | Initial | $100,000 | No comparison | 1 | SEC filing |
| May 1, 2015 | Initial | $257,000 | No comparison | 1 | SEC filing |
| Mar 16, 2015 | Initial | $218,269 | No comparison | 11 | SEC filing |
| Mar 16, 2015 | Initial | $3,150,000 | No comparison | 7 | SEC filing |
| Mar 16, 2015 | Initial | $1,355,279 | No comparison | 28 | SEC filing |
| Mar 16, 2015 | Initial | $908,653 | No comparison | 27 | SEC filing |
| Mar 16, 2015 | Initial | $2,500,023 | No comparison | 15 | SEC filing |
| Mar 16, 2015 | Amendment | $1,500,000 | $1,400,000vs Feb 19, 2013 | 2 | SEC filing |
| Feb 19, 2013 | Initial | $100,000 | No comparison | 2 | SEC filing |
| Dec 6, 2011 | Initial | $1,000,000 | No comparison | 17 | SEC filing |
| May 5, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $375K
- Finders' fees
- $0
- Form D file number
- 021-492046
Includes aggregate exercise price of warrants of $1.47 per share, that may be received upon exercise of the warrants.
Comprised of a total cash fee equal to 7.5% of the aggregate gross proceeds of the private placement. The issuer issued to placement agent (and its designees) warrants to purchase up to 218,023 shares at an exercise price of $2.15 under Section 4(a)(2).
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Sep 13, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Brown | Executive |
| James Cardwell | Executive |
| Aurora Cassirer | Director |
| Christopher Fashek | Director |
| Sim Fass | Director |
| Michael Ferguson | Director |
| Martin Goldstein | Director |
| Ira Greenstein | Director |
| Harold Jacob | Director |
| Thomas R. Mika | Director |
| Brian Murphy | Director, Executive |
| Paul Packer | Director |
| Maria Schroeder | Director |
| William Stern | Director, Executive |
| Mika R. Thomas | Director |
| Jona Zumeris | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
525 Executive Blvd.
Elmsford, NY, 10523
Elmsford, NY, 10523